D.E. Shaw & Co
SCMP

D.E. Shaw & Co’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

D.E. Shaw & Co’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,000
Closed -$994K – 4065
2015
Q3 		$994K Buy
+50,000
New +$1.15M ﹤0.01% 2612

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's SCMP Position: Q2 2017 in Review

D.E. Shaw & Co sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 18,363 shares — an estimated $202K sold.

D.E. Shaw & Co first reported a position in SCMP in Q2 2013 and held it in 14 quarters. The position peaked at $3.54M in Q3 2015. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

  • D.E. Shaw & Co reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 18,363 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $202K.
  • D.E. Shaw & Co first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
  • D.E. Shaw & Co's Sucampo Pharmaceuticals, Inc. position peaked at $3.54M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on D.E. Shaw & Co's 13F filing for Q2 2017, filed 14 Aug 2017.